Department of Biomedical Sciences, Clinical Genetics Service, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy.
Genomic Medicine, Policlinico Universitario "A. Gemelli" Foundation IRCCS, Rome, Italy.
Eur J Hum Genet. 2023 Jun;31(6):648-653. doi: 10.1038/s41431-023-01305-z. Epub 2023 Feb 16.
Loss-of-function variants in CHAMP1 were recently described as cause of a neurodevelopmental disorder characterized by intellectual disability (ID), autism, and distinctive facial characteristics. By exome sequencing (ES), we identified a truncating variant in CHAMP1, c.1858A > T (p.Lys620*), in a patient who exhibited a similar phenotype of severe ID and dysmorphisms. Whether haploinsufficiency or a dominant negative effect is the underlying pathomechanism in these cases is a question that still needs to be addressed. By array-CGH, we detected a 194 kb deletion in 13q34 encompassing CHAMP1, CDC16 and UPF3, in another patient who presented with borderline neurodevelopmental impairment and with no dysmorphisms. In a further patient suffering from early onset refractory seizures, we detected by ES a missense variant in CHAMP1, c.67 G > A (p.Gly23Ser). Genomic abnormalities were all de novo in our patients. We reviewed the clinical and the genetic data of patients reported in the literature with: loss-of-function variants in CHAMP1 (total 40); chromosome 13q34 deletions ranging from 1.1 to 4 Mb (total 7) and of the unique patient with a missense variant. We could infer that loss-of-function variants in CHAMP1 cause a homogeneous phenotype with severe ID, autism spectrum disorders (ASD) and highly distinctive facial characteristics through a dominant negative effect. CHAMP1 haploinsufficiency results in borderline ID with negligible consequences on the quality of life. Missense variants give rise to a severe epileptic encephalopathy through gain-of-function mechanism, most likely. We tentatively define for the first time distinct categories among the CHAMP1-related disorder on the basis of pathomechanisms.
CHAMP1 中的功能丧失性变异最近被描述为导致神经发育障碍的原因,其特征为智力障碍 (ID)、自闭症和独特的面部特征。通过外显子组测序 (ES),我们在一名表现出类似严重 ID 和发育不良特征的患者中发现了 CHAMP1 中的截断变异,c.1858A>T (p.Lys620*)。这些病例中是否存在杂合子功能不全或显性负效应作为潜在的发病机制,这仍然是一个需要解决的问题。通过 array-CGH,我们在另一名存在边缘神经发育障碍且无发育不良特征的患者中检测到 13q34 上的 194kb 缺失,该缺失涵盖了 CHAMP1、CDC16 和 UPF3。在另一名患有早期发病的难治性癫痫的患者中,我们通过 ES 检测到 CHAMP1 中的错义变异,c.67G>A (p.Gly23Ser)。我们患者的基因组异常均为新生。我们回顾了文献中报道的具有 CHAMP1 功能丧失性变异的患者的临床和遗传数据(总数为 40 例);13q34 缺失从 1.1 到 4Mb 不等(总数为 7 例),以及具有独特错义变异的唯一患者的遗传数据。我们可以推断,CHAMP1 中的功能丧失性变异通过显性负效应导致具有严重 ID、自闭症谱系障碍 (ASD) 和高度独特面部特征的同质表型。CHAMP1 杂合子功能不全导致边缘 ID,对生活质量的影响可以忽略不计。错义变异很可能通过获得性功能机制导致严重的癫痫性脑病。我们首次根据发病机制对 CHAMP1 相关疾病进行了明确分类。